This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Merck's Future Looks Healthier

NEW YORK ( TheStreet) -- When I last discussed Merck's (MRK) growth prospects, I told you the stock was a relative bargain given that shares of Johnson & Johnson (JNJ), Pfizer (PFE) and Bristol-Myers Squibb (BMY) were all (then) trading near 52-week highs.

Merck wasn't a popular stock at the time due to concerns about the company's pipeline and expiring patents, but I believed it was still worthwhile. Since that call, shares of Merck have increased 20%. Last week, an FDA advisory panel recommended the approval of Merck's new allergy drug Ragwitek, so I expect the company's winning streak to continue.

[Read: 3 Winners on Stronger Chinese Currency]

Analyst David Risinger of Morgan Stanley, who has a $60 price target on Merck, recently cited the company's immuno-oncology candidate MK-3475 as a reason to own the stock. While acknowledging that Merck's valuation may not be as compelling to value-oriented investors, Risinger warned against being too cautious. I agree. As I pointed out several months ago, there's still a long-term growth story developing with Merck.

I'm not trying to convince you Merck is superior to Pfizer and GlaxoSmithKline (GSK). That argument goes beyond the scope of this article. What I do know, though, is that Merck's management hasn't been dozing off at the wheel in the trailing twelve months. And with some strategic moves and a rededication to research and development, they've now positioned this company to regain the market share it has lost.

The Street has finally taken notice -- albeit long after my initial call. The company will report fourth-quarter and full-year earnings on Wednesday. Merck's management has remained steadfast about returning value to shareholders. They've done a solid job up to this point. But it's going to take more convincing to get new investors to buy in at near 52-week highs.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs